Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Resolution of Refractory Eosinophilic Esophagitis with the Leukocyte-Trafficking Inhibitor Natalizumab.

Literature DB >> 31190203

Resolution of Refractory Eosinophilic Esophagitis with the Leukocyte-Trafficking Inhibitor Natalizumab.

Ian L P Beales¹.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2019 PMID： 31190203 DOI： 10.1007/s10620-019-05704-5

Source DB: PubMed Journal: Dig Dis Sci ISSN： 0163-2116 Impact factor: 3.199

× No keyword cloud information.

11 in total

1. The alpha4bbeta7-integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestine.

Authors: E B Brandt; N Zimmermann; E E Muntel; Y Yamada; S M Pope; A Mishra; S P Hogan; M E Rothenberg
Journal: Clin Exp Allergy Date: 2006-04 Impact factor: 5.018

Review 2. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

Authors: George P A Rice; Hans-Peter Hartung; Peter A Calabresi
Journal: Neurology Date: 2005-04-26 Impact factor: 9.910

Review 3. Natalizumab for induction of remission in Crohn's disease.

Authors: J K MacDonald; J W D McDonald
Journal: Cochrane Database Syst Rev Date: 2007-01-24

4. The Potential Role of Vedolizumab in Concomitant Eosinophilic Esophagitis and Crohn's Disease.

Authors: Tiffany H Taft; Ece A Mutlu
Journal: Clin Gastroenterol Hepatol Date: 2018-11 Impact factor: 11.382

5. T-helper 2 cytokines, transforming growth factor β1, and eosinophil products induce fibrogenesis and alter muscle motility in patients with eosinophilic esophagitis.

Authors: Florian Rieder; Ilche Nonevski; Jie Ma; Zhufeng Ouyang; Gail West; Cheryl Protheroe; Giovanni DePetris; Anja Schirbel; James Lapinski; John Goldblum; Tracey Bonfield; Rocio Lopez; Karen Harnett; James Lee; Ikuo Hirano; Gary Falk; Piero Biancani; Claudio Fiocchi
Journal: Gastroenterology Date: 2014-01-28 Impact factor: 22.682

6. Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis.

Authors: Hannah P Kim; Craig C Reed; Hans H Herfarth; Evan S Dellon
Journal: Clin Gastroenterol Hepatol Date: 2018-03-27 Impact factor: 11.382

Review 7. Eosinophilic esophagitis: latest insights from diagnosis to therapy.

Authors: Alain Schoepfer; Carine Blanchard; Heather Dawson; Alfredo Lucendo; Aurelio Mauro; Camillo Ribi; Ekaterina Safroneeva; Edoardo V Savarino; Roberto Penagini
Journal: Ann N Y Acad Sci Date: 2018-05-15 Impact factor: 5.691

Review 8. Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease.

Authors: Lauren N Cherry; Nancy S Yunker; Erika R Lambert; DaleMarie Vaughan; Denise K Lowe
Journal: Ther Adv Chronic Dis Date: 2015-09 Impact factor: 5.091

9. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.

Authors: Pei-Ran Ho; Harold Koendgen; Nolan Campbell; Bill Haddock; Sandra Richman; Ih Chang
Journal: Lancet Neurol Date: 2017-09-29 Impact factor: 44.182

Review 10. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.

Authors: Irene Tramacere; Cinzia Del Giovane; Georgia Salanti; Roberto D'Amico; Graziella Filippini
Journal: Cochrane Database Syst Rev Date: 2015-09-18

1 in total

Review 1. Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets.

Authors: Francesca Racca; Gaia Pellegatta; Giuseppe Cataldo; Edoardo Vespa; Elisa Carlani; Corrado Pelaia; Giovanni Paoletti; Maria Rita Messina; Emanuele Nappi; Giorgio Walter Canonica; Alessandro Repici; Enrico Heffler
Journal: Front Physiol Date: 2022-01-12 Impact factor: 4.566

1 in total